Dynamic Changes in Circulating Endocrine FGF19 Subfamily and Fetuin-A in Response to Intralipid and Insulin Infusions in Healthy and PCOS Women
| Autor: | Myint M Aye, Stephen L. Atkin, Monica Skarulis, Kodappully Sivaraman Siveen, Tareq A. Samra, Thozhukat Sathyapalan, Meis Alkasem, Abdul-Badi Abou-Samra, Jayakumar Jerobin, Manjunath Ramanjaneya, Milin Bensila, Ilham Bettahi |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Adult
0301 basic medicine FGF (fibroblast growth factor) medicine.medical_specialty Fetuin A FGF21 Adolescent alpha-2-HS-Glycoprotein Health Status Endocrinology Diabetes and Metabolism medicine.medical_treatment 030209 endocrinology & metabolism Type 2 diabetes Fibroblast growth factor lcsh:Diseases of the endocrine glands. Clinical endocrinology FGF19 PCOS (polycystic ovarian syndrome) Young Adult 03 medical and health sciences Endocrinology 0302 clinical medicine Insulin resistance Internal medicine medicine Humans Insulin Endocrine system Infusions Intravenous Exercise Original Research lcsh:RC648-665 business.industry hyperinsulimic-euglycemic clamp Lipid Metabolism medicine.disease Lipids Polycystic ovary Fibroblast Growth Factors Fibroblast Growth Factor-23 030104 developmental biology Female business Biomarkers Polycystic Ovary Syndrome Hormone |
| Zdroj: | Frontiers in Endocrinology Frontiers in Endocrinology, Vol 11 (2020) |
| ISSN: | 1664-2392 |
| DOI: | 10.3389/fendo.2020.568500 |
| Popis: | Background: The fibroblast growth factors (FGF) 19 subfamily, also referred to as endocrine FGFs, includes FGF19, FGF21, and FGF23 are metabolic hormones involved in the regulation of glucose and lipid metabolism. Fetuin-A is a hepatokine involved in the regulation of beta-cell function and insulin resistance. Endocrine FGFs and fetuin-A are dysregulated in metabolic disorders including obesity, type 2 diabetes, non-alcoholic fatty liver disease and polycystic ovary syndrome (PCOS). Our study was designed to examine the response of endocrine FGFs and fetuin-A to an acute intralipid, insulin infusion and exercise in PCOS and healthy women. Subjects and Measurements: Ten healthy and 11 PCOS subjects underwent 5-h saline infusions with a hyperinsulinemic-euglycemic clamp (HIEC) performed during the final 2 h. One week later, intralipid infusions were undertaken with a HIEC performed during the final 2 h. After an 8 week of exercise intervention the saline, intralipid, and HIEC were repeated. Plasma levels of endocrine FGFs and fetuin-A were measured. Results: Baseline fetuin-A was higher in PCOS women but FGF19, FGF21, and FGF23 did not differ and were unaffected by exercise. Insulin administration elevated FGF21 in control and PCOS, suppressed FGF19 in controls, and had no effects on FGF23 and fetuin-A. Intralipid infusion suppressed FGF19 and increased FGF21. Insulin with intralipid synergistically increased FGF21 and did not have effects on lipid-mediated suppression of FGF19 in both groups. Conclusion: Our study provides evidence for insulin and lipid regulation of endocrine FGFs in healthy and PCOS women, suggesting that FGF family members play a role in lipid and glucose metabolism. Clinical Trial Registration: www.isrctn.org, Identifier: ISRCTN42448814. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|